These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29666602)

  • 21. Severe Gastritis after Administration of Nivolumab and Ipilimumab.
    Nishimura Y; Yasuda M; Ocho K; Iwamuro M; Yamasaki O; Tanaka T; Otsuka F
    Case Rep Oncol; 2018; 11(2):549-556. PubMed ID: 30186138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature.
    Papavasileiou E; Prasad S; Freitag SK; Sobrin L; Lobo AM
    Ocul Immunol Inflamm; 2016; 24(2):140-6. PubMed ID: 25760920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
    Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
    Front Immunol; 2018; 9():411. PubMed ID: 29552014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late-Onset Inflammatory Bowel Disease-Like Syndrome after Ipilimumab Therapy: A Case Report.
    Akel R; Anouti B; Tfayli A
    Case Rep Oncol; 2017; 10(2):456-461. PubMed ID: 28626406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
    Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remote-onset alopecia areata attributed to ipilimumab.
    Pearson DR; Lewis K; Alkousakis T
    Cutis; 2019 Dec; 104(6):E25-E27. PubMed ID: 31939941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
    Boasberg P; Hamid O; O'Day S
    Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN; Mukkamalla SKR; Armenio VA
    J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
    Hwang SJ; Carlos G; Wakade D; Sharma R; Fernandez-Penas P
    Melanoma Res; 2016 Aug; 26(4):417-20. PubMed ID: 27031538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
    Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
    J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report.
    Zecchini JM; Kim S; Yum K; Friedlander P
    J Immunother; 2018 Jan; 41(1):39-41. PubMed ID: 28926356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.
    Bjoern J; Iversen TZ; Nitschke NJ; Andersen MH; Svane IM
    Cytotherapy; 2016 Aug; 18(8):1043-1055. PubMed ID: 27378345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myasthenia Gravis Induced by Nivolumab: A Case Report.
    Mehta JJ; Maloney E; Srinivasan S; Seitz P; Cannon M
    Cureus; 2017 Sep; 9(9):e1702. PubMed ID: 29159009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab.
    Slangen RM; van den Eertwegh AJ; van Bodegraven AA; de Boer NKh
    World J Gastrointest Pharmacol Ther; 2013 Aug; 4(3):80-2. PubMed ID: 23919220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "Warming yang and invigorating qi" acupuncture alters acetylcholine receptor expression in the neuromuscular junction of rats with experimental autoimmune myasthenia gravis.
    Huang HP; Pan H; Wang HF
    Neural Regen Res; 2016 Mar; 11(3):465-8. PubMed ID: 27127487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy-associated autoimmune hemolytic anemia.
    Khan U; Ali F; Khurram MS; Zaka A; Hadid T
    J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.